Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

BACKGROUND: Erlotinib and pemetrexed have been approved for the second-line treatment of non-small cell lung cancer (NSCLC). These two agents have different mechanisms of action. Combined treatment with erlotinib and pemetrexed could potentially augment the antitumor activity of either agent alone....

Descripción completa

Detalles Bibliográficos
Autores principales: Minami, Seigo, Kijima, Takashi, Takahashi, Ryo, Kida, Hiroshi, Nakatani, Takeshi, Hamaguchi, Masanari, Takeuchi, Yoshiko, Nagatomo, Izumi, Yamamoto, Suguru, Tachibana, Isao, Komuta, Kiyoshi, Kawase, Ichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437193/
https://www.ncbi.nlm.nih.gov/pubmed/22809298
http://dx.doi.org/10.1186/1471-2407-12-296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437193/
https://www.ncbi.nlm.nih.gov/pubmed/22809298
http://dx.doi.org/10.1186/1471-2407-12-296

Ejemplares similares